Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02215


Purpose:

RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells. PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma.


Study summary:

OBJECTIVES: - Determine the clinical activity of rosiglitazone in patients with liposarcoma. - Assess the impact of this regimen on markers of tumor proliferation and differentiation status in these patients using biologic and biochemical testing and correlative imaging. - Determine the tolerance and safety of this regimen in these patients. OUTLINE: Patients are stratified by histologic subtype (well differentiated vs dedifferentiated vs myxoid/round cell vs pleomorphic). Patients receive oral rosiglitazone twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at 1-3 weeks and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 56-120 patients (14-30 per stratum) will be accrued for this study within 15 months.


Criteria:

DISEASE CHARACTERISTICS: - Histologically proven liposarcoma that is incurable with standard multimodality approaches (e.g., surgery and/or radiotherapy and/or chemotherapy) - Well differentiated OR - Dedifferentiated OR - Myxoid/round cell OR - Pleomorphic - Measurable disease - No clinically unstable brain metastases - No progression on prior troglitazone therapy for liposarcoma PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - At least 3 months Hematopoietic: - Absolute neutrophil count at least 1,000/mm3 - Platelet count at least 90,000/mm3 Hepatic: - Bilirubin no greater than 2.0 mg/dL - SGOT less than 5 times upper limit of normal Renal: - Creatinine no greater than 2.4 mg/dL Cardiovascular: - No poorly controlled atrial arrhythmias, symptomatic angina pectoris, or myocardial infarction within the past 4 months - No symptomatic congestive heart failure, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within the past 3 months Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception - Oral contraceptives are not considered effective contraception - No active retroviral disease - No condition that would preclude informed consent PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics - Prior chemotherapy allowed and recovered - No concurrent cytotoxic therapy Endocrine therapy: - No concurrent hormonal therapy Radiotherapy: - See Disease Characteristics - Prior radiotherapy allowed and recovered - At least 6 months since prior radiotherapy to the sole site of measurable disease - Concurrent localized radiotherapy to a single site of disease allowed if there are other sites of measurable disease Surgery: - Not specified


NCT ID:

NCT00004180


Primary Contact:

Study Chair
George D. Demetri, MD
Dana-Farber Cancer Institute


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02215
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.